Investor Information

  • Psyence Clinical Trials

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

2022-09-19T13:05:24+02:00September 19, 2022|Press Releases, Investor Information|

Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

2021-12-02T15:19:55+02:00December 2, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

  • Global Wellness Summit - Psilocybin - Boston

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

2021-11-27T05:48:16+02:00November 26, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing. 

Go to Top